We are ready!
“With their distinct identities, Galenica Santé and Vifor Pharma address shareholders who expect differentiated, high-quality performances, namely continued development with an attractive dividend policy as well as strong growth and a high margin.”
Ladies and Gentlemen,
2016 marks a critical new phase in the development of the Galenica Group, with the 21st successive increase in profit in 21 years, excluding the significant impact of the Relypsa acquisition. All activities grew more rapidly than their respective markets.
Major challenges emerged during the course of the year:
These challenges were met to our great satisfaction, once again demonstrating the entrepreneurial spirit and effectiveness of which the entire Galenica Group is capable. The Group is now ready to transform itself into two independent listed companies, each with its own strategy, projects, competences and strengths, as illustrated in the following short profiles.
profit growth before deduction of minority interests (on a comparable basis, without negative influence of Relypsa and IAS 19)
cumulative growth in the share price from 1995 (start of the transformation strategy) to 2016
The global leader in iron therapies has built itself a first-rate portfolio of products and projects:
Products and areas each with growth potential of more than one billion Swiss francs over several years:
Highly attractive projects with patents due to expire in 2028/34 or later:
A range of well-known products that are proven leaders in their respective areas: Venofer®, Maltofer®, Uro-Vaxom®, Broncho-Vaxom®, Doxium®, etc.
Health partner par excellence in the Swiss market, Galenica Santé is a leader in all its activities:
A targeted market approach, consolidated year after year for more than two
decades, has enabled Galenica Santé to work in harmony and to create synergies with different players and customers, for each of whom it is also number one, for example:
The two companies also set themselves apart by their capacity to generate added value through their specific business models and collaborations with leaders in their respective sectors, such as Vifor Pharma with Fresenius Medical Care and Galenica Santé with Coop.
With their distinct identities, Galenica Santé and Vifor Pharma address shareholders who expect differentiated, high-quality performances, namely continued development with an attractive dividend policy as well as strong growth and a high margin.
These companies have been created by first-rate managers and teams, whom I would like to thank for their exceptional commitment on behalf of both the Board of Directors and you, as a shareholder. I believe that you will allow me to take the
liberty to do so.
Bern, 14 March 2017